Member Info for Parpaing

I sent the email request.

to Paul Mnies and his team. They have worked hard in a difficult market with new products. This isn't an easy task, but they are winning with good products. I'm surprised they haven't been taken over.

I got the letter from my broker. 1new share for 250 old shares. Effective date 7th April 2016. New shares available from the 7th April 2016.

Will it start off with a sentence such as: "How to turn ten grand into 200 quid - invest in TRP and "Glowing-in-the-dark" Thomson.

The point of the post is that RUsnano runs the show - not Scott. As Rusnano is owned by the Russian government then you can assume that if further investment is required, then it will be made available, as in the past.

Rusnano runs our investment and therefore has the funds to continue the development of xbio - see below: Production of innovative drugs and biobetters based on biodegradable nanocomposites The project is an outstanding example of Russian-British-German collaboration in innovative pharmaceuticals. SynBio will develop and bring nine drug preparations based on three technological platforms to Russian and international markets. Sustained-release drugs containing polysialic acid—biobetters for treatment of diabetes mellitus, Alzheimer’s disease, chronic kidney disease, and other illnesses (PolyXen® platform). Drugs based on recombinant human Histone H1 for treatment of cancers and other illnesses, including blood cancers (leukemia, lymphoma, and myeloma) and ischemic diseases (Histone platform). Cell therapeutic product for the treatment of liver cirrhosis (Gemacell platform). The drugs in the portfolio are all in various stages of pre-clinical and clinical studies in Russia and Europe. Sales by portfolio company SynBio in 2015 are forecast at 700 million rubles (about $24 million). SynBio has acquired a controlling interest in Xenetic Biosciences PLC. As a result, a Russian company has become, for the first time, the initiator of a new and powerful player in the international innovative pharmaceutical industry. Area of application Medicine Market Pharmaceutical distribution companies Competitive advantages Greater effectiveness of the drugs Source: http://en.rusnano.com/portfolio/companies/synbio

How about we ask the Stock Exchange to investigate this company? How do we know that any drilling has ever taken place? AIM has proved to be nothing but a shoddy license to scam investors and is worse than timeshare. TRP have invented shares and more shares and managed to con folks into buying into thin air. The only thing that appears to exist in this company is waffle. yes, i do remeber the 'glowing in the dark' remark. That was a clear confidence trick.

Announces Dosing of First Patient in BAX 826 Phase 1 as Hemophilia A Treatment. http://www.streetinsider.com/Corporate+News/Baxalta+%28BXLT%29+Announces+Dosing+of+First+Patient+in+BAX+826+Phase+1+as+Hemophilia+A+Treatment/11390676.html

no beginning to Ross McEwan's talents? Anyone can make a loss in a bank but they shouldn't get paid so much for it. I'm not just jealous of his free seats at the RBS Rugby matches, lucky bar steward!

Scott Maguire, CEO of Xenetic Biosciences, stated, "It is with great pleasure that Xenetic welcomes an outstanding talent like Dr. Kornberg to our board. Dr. Kornberg brings to Xenetic the rare combination of large cap board expertise and intimate knowledge of our science; which will serve the company well as we work to up-list to a more liquid-globally recognized stock exchange and strive to realize our pipeline's potential as we move to market launch."

LEXINGTON, MA -- (Marketwired) -- 02/29/16 -- Xenetic Biosciences, Inc. (OTCQB: XBIO), a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics, today announced the appointment of renowned chemist and Nobel Laureate, Dr. Roger D. Kornberg to the Company's Board of Directors. source: xenetic email.

Opko Health, Inc. (NYSE:OPK) advanced +0.11% to close the trading session at $8.84. On February 23, 2016, Xenetic Biosciences, Inc. (XBIO) on 24 February 2016, announced that GeneDx was invited to participate in the Molecular Medicine Tri-Conference 2016, being held at the Moscone North Convention Center in San Francisco, California from March 6th – 11th, 2016, and will also be exhibiting at Booth 606. http://www.istreetwire.com/3-biotech-stocks-worth-chasing-geron-corporation-gern-relypsa-inc-rlyp-opko-health-inc-opk/

Baxalta to Initiate a First-in-Human Clinical Trial of BAX 826, an Investigational, Extended Half-Life FVIII Treatment Targeting Weekly Dosing for Hemophilia A source: http://newsroom.baxalta.com/press-releases/press-release-details/2015/Baxalta-to-Initiate-a-First-in-Human-Clinical-Trial-of-BAX-826-an-Investigational-Extended-Half-Life-FVIII-Treatment-Targeting-Weekly-Dosing-for-Hemophilia-A/default.aspx

here: http://newsroom.baxalta.com/press-releases/press-release-details/2015/Baxalta-to-Initiate-a-First-in-Human-Clinical-Trial-of-BAX-826-an-Investigational-Extended-Half-Life-FVIII-Treatment-Targeting-Weekly-Dosing-for-Hemophilia-A/default.aspx

Xbio dosed first patient on February 23rd phase 2a study factor VIIa safety study. http://www.istreetwire.com/scorching-hot-biotech-tape-amgen-inc-amgn-celldex-therapeutics-inc-cldx-opko-health-inc-opk/

5 shares each at $10k a pop - I can live with that.

Perhaps someone else would like to contact Scott or someone at the company email; info@xeneticbio.com 99 Hayden Ave, STE 230 Lexington, MA 02421 United States Phone: 781-778-7720

Commenting on the investment in Xenetic, Dr. Phillip Frost, CEO and Chairman of OPKO Health, Inc., stated, “Xenetic has many novel technologies that address unmet needs in various orphan cancer indications, and we believe the science and the clinical strategy have the promise to create significant shareholder value.”

Yes, I agree. I am willing to wait for the nasdaq uplift but meanwhile, we may lose buy and sell opportunities along the way without a dealing platform.

I called Scott's office. He is travelling at the moment but, Jean McClusky, who answered the call, promised to send Scott a message. I asked for an update on the company and explained that the UK group of investors are not able to trade XBIO and I would like to know how is going to address that issue. Jean explained that 'they' XBIO are trying to move up to the NASDAQ but no more info than that and she did not want to go further into the call. However, I gave Jean my email address and she said that Scott would write to me/us.